OULU, Finland—Late last year, Admescope Ltd., a provider of ADME-Tox contract research services, announced the launch of services for a new category: Biologics.
The number of drug development projects with biological drugs has been continuously increasing over the past decade, and therefore the expansion to serve this growing market was considered “a logical continuation” for Admescope’s service development, after having previously built a strong and comprehensive service portfolio for the research of small molecules and peptides.
At launch, Admescope’s service offering for biological drugs consists of protein molecular weight and structural characterization, targeted protein quantification, peptide mapping and detection of post-translational modifications, and protein pharmacokinetics.
Dr. Ari Tolonen, CEO of Admescope, said “We are thrilled to add another notable step on our growth path this year, following the successful acquisition of MetaSafe AB in June. With the group of experienced protein scientists that we have recruited for our Biologics’ team, we are able to serve the growing segment of biological drug development with the same high quality and expertise that our customers are used to with our services for small molecules and peptides.”
